Abstract
Medicine was always aspired to be personalized, directed to each patient as a unique case. In our time, advancement of biomedical sciences and computational and other technologies has provided solid foundation for personalized medicine. Personalized medicine, also called genome-based medicine and precision medicine, uses the knowledge of genomic and epigenomic basis of the disease to individualize treatment for each patient. Hematological malignancies and especially acute myeloid leukemia are the best examples of implementation of personalized medicine in clinical practice. Acute myeloid leukemia (AML) is a heterogeneous group of malignant diseases of hematopoietic progenitor cells, characterized by different molecular genetic and epigenetic abnormalities. It is the most common type of acute leukemia in adults, and the second most common in children. Until recently, the treatment of AML was based on standard cytotoxic chemotherapy, having resulted in the overall survival of only 30–40% in the majority of patients. Application of new high-throughput technologies has enabled better insight into genetic and epigenetic landscape of AML. The most important achievement of genome-based medicine is more precise classification of AML patients based on newly discovered molecular markers, and molecular–targeted therapy, tailored to genetic and epigenetic profile of a disease, leading to improved survival of the AML patients. Additionally, development of pharmacogenomic platforms, immunotherapies and cellular therapies has open new possibilities for personalized treatment of AML patients. There is no doubt that we are getting closer to full implementation of personalized medicine in hematological clinical practice.
The aim of personalized medicine is the tailoring of medical treatment to the individual characteristics of each patient. The concept of personalized medicine dates back many hundreds of years. It was Hippocrates (IV century BC) who sent a message to the future generations of physicians: “It’s far more important to know what sort of person has a disease, than what sort of disease a person has”.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Notes
- 1.
Perry and Attar (2014).
- 2.
Byrd et al. (2002).
- 3.
Arber et al. (2016).
- 4.
Dohner et al. (2017).
- 5.
Ley et al. (2008).
- 6.
Ley et al. (2010).
- 7.
Mardis et al. (2009).
- 8.
Welch et al. (2011).
- 9.
Marcucci et al. (2010).
- 10.
Warner et al. (2004).
- 11.
Traulsen et al. (2010).
- 12.
Cancer Genome Atlas Research Network (2013).
- 13.
Marjanovic et al. (2016).
- 14.
Wolf et al. (2000).
- 15.
Cohen (1966).
- 16.
Borun et al. (1969).
- 17.
Creasey et al. (1968).
- 18.
Emadi and Karp (2012).
- 19.
Lamba (2009).
- 20.
Kim et al. (2016).
- 21.
Wan et al. (2014).
- 22.
Montero et al. (2012).
- 23.
Galmarini et al. (2002).
- 24.
Lamba et al. (2007).
- 25.
Galmarini et al. (2005).
- 26.
Mitra et al. (2011).
- 27.
Maring et al. (2005).
- 28.
Abraham et al. (2012).
- 29.
Abraham et al. (2012).
- 30.
Li et al. (2008).
- 31.
Hartford et al. (2009).
- 32.
Takagaki et al. (2003).
- 33.
Yin et al. (2007).
- 34.
Sharom (2008).
- 35.
Megías et al. (2015).
- 36.
L’Ecuyer et al. (2004).
- 37.
Voso et al. (2008).
- 38.
Iacobucci et al. (2013).
- 39.
Wang and Chen (2008).
- 40.
Carbone et al. (2006).
- 41.
Villa et al. (2007).
- 42.
Scaglioni and Pandolfi (2007).
- 43.
Grignani et al. (1998).
- 44.
Tallman et al. (2002).
- 45.
Estey et al. (2006).
- 46.
Chen et al. (1997).
- 47.
Speck and Gililand (2002).
- 48.
Meyers et al. (1995).
- 49.
Lutterbach et al. (1999).
- 50.
Strahl and Allis (2000).
- 51.
Figueroa et al. (2008).
- 52.
Carow et al. (1996).
- 53.
Schnittger et al. (2002).
- 54.
Colovic et al. (2007).
- 55.
Krstovski et al. (2010).
- 56.
Yamamoto et al. (2001).
- 57.
Dicker et al. (2007).
- 58.
Moore et al. (2012).
- 59.
Smith et al. (2015).
- 60.
Stone et al. (2015).
- 61.
Zhang et al. (2008a).
- 62.
Zhang et al. (2008b).
- 63.
Ravandi et al. (2013).
- 64.
Macdonald et al. (2013).
- 65.
Zarrinkar et al. (2009).
- 66.
Randhawa et al. (2014).
- 67.
Levis et al. (2015).
- 68.
Mesa and Kaufmann (2007).
- 69.
Bacher et al. (2006).
- 70.
Borthakur et al. (2016).
- 71.
Badar et al. (2015).
- 72.
Groschel et al. (2015).
- 73.
Bertwistle et al. (2004).
- 74.
Colombo et al. (2002).
- 75.
Ziv et al. (2014).
- 76.
Falini et al. (2007).
- 77.
Falini et al. (2009).
- 78.
Kuzmanovic et al. (2012).
- 79.
Falini et al. (2011).
- 80.
Falini and Martelli (2011).
- 81.
Balusu et al. (2011).
- 82.
Wei et al. (2015).
- 83.
Martelli et al. (2015).
- 84.
El Hajj et al. (2015).
- 85.
Egger et al. (2004).
- 86.
Issa et al. (2004).
- 87.
Kantarjian et al. (2012).
- 88.
Bolden et al. (2006).
- 89.
Cimino et al. (2006).
- 90.
Fredly et al. (2013).
- 91.
Lindsley and Ebert (2013).
- 92.
Valent and Zuber (2014).
- 93.
Dawson et al. (2011).
- 94.
Dombret et al. (2014).
- 95.
Krivtsov and Armstrong (2007).
- 96.
Basecke et al. (2006).
- 97.
Daigle et al. (2013).
- 98.
Stein and Tallman (2015).
- 99.
Puda et al. (2012).
- 100.
Knutson et al. (2012).
- 101.
Ward et al. (2010).
- 102.
Abbas et al. (2010).
- 103.
Dang et al. (2009).
- 104.
Xu et al. (2011).
- 105.
Chowdhury et al. (2011).
- 106.
Thol et al. (2010).
- 107.
Wagner et al. (2010).
- 108.
Schnittger et al. (2010).
- 109.
Virijevic et al. (2016).
- 110.
Nomdedeu et al. (2011).
- 111.
Chaturvedi et al. (2013).
- 112.
Chaturvedi et al. (2014).
- 113.
Davis et al. (2014).
- 114.
Wang et al. (2013).
- 115.
Stein (2015).
- 116.
Chan et al. (2015).
- 117.
Itzykson et al. (2011).
- 118.
Damm et al. (2014).
- 119.
Gaidzik et al. (2012).
- 120.
Figueroa et al. (2010).
- 121.
Bestor (2000).
- 122.
Marcucci et al. (2012).
- 123.
Russler-Germain et al. (2014).
- 124.
Challen et al. (2011).
- 125.
Shlush et al. (2014).
- 126.
Xie et al. (2014).
- 127.
Ploen et al. (2014).
- 128.
Metzeler et al. (2012).
- 129.
Hanahan and Weinberg (2011).
- 130.
Bross et al. (2001).
- 131.
Petersdorf et al. (2013).
- 132.
Pollard et al. (2016).
- 133.
Kung Sutherland et al. (2013).
- 134.
Stein et al. (2015).
- 135.
Krupka et al. (2014).
- 136.
Jordan et al. (2000).
- 137.
Kugler et al. (2010).
- 138.
Gleason et al. (2014).
- 139.
Kuball et al. (2011).
- 140.
Keilholz et al. (2009).
- 141.
Uttenthal et al. (2014).
- 142.
Borrello et al. (2009).
- 143.
Hardwick et al. (2010).
- 144.
Skalova et al. (2010).
- 145.
Serrano-López et al. (2011).
- 146.
Ruben et al. (2014).
- 147.
Lee et al. (2004).
- 148.
Van Driessche et al. (2009).
- 149.
Van Tendeloo et al. (2010).
- 150.
Berneman et al. (2012).
- 151.
Eshhar et al. (1993).
- 152.
Jena et al. (2010).
- 153.
Uttenthal et al. (2012).
- 154.
Sadelain et al. (2013).
- 155.
Gill and June (2015).
- 156.
Brentjens et al. (2013).
- 157.
Rotiroti et al. (2017).
- 158.
Dutour et al. (2012).
- 159.
O’Hear et al. (2015).
- 160.
Kenderian et al. (2015).
- 161.
Pizzitola et al. (2014).
- 162.
Mardiros et al. (2015).
- 163.
Kim et al. (2005).
- 164.
Ruggeri et al. (2002).
- 165.
Rubnitz et al. (2010).
- 166.
Curti et al. (2011).
References
Abbas S, Lugthart S, Kavelaars FG et al (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116(12):2122–2126. https://doi.org/10.1182/blood-2009-11-250878
Abraham A, Varatharajan S, Abbas S et al (2012) Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 13(3):269–282. https://doi.org/10.2217/pgs.11.149
Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544
Bacher U, Haferlach T, Schoch C et al (2006) Implications of NRAS mutations in AML: a study of 2502 patients. Blood 107(10):3847–3853. https://doi.org/10.1182/blood-2005-08-3522
Badar T, Cortes JE, Ravandi F et al (2015) Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk 15(7):433–438. https://doi.org/10.1016/j.clml.2015.02.018
Balusu R, Fiskus W, Rao R et al (2011) Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 118(11):3096–3106. https://doi.org/10.1182/blood-2010-09-309674
Basecke J, Whelan JT, Griesinger F, Bertrand FE (2006) The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 135(4):438–449. https://doi.org/10.1111/j.1365-2141.2006.06301.x
Berneman ZN, Van de Velde A, Anguille S et al (2012) WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. 2012 ASCO Annual Meeting, 1-5 June 2012, Chicago IL, USA. J Clin Oncol 30:2506
Bertwistle D, Sugimoto M, Sherr CJ (2004) Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 24(3):985–996. https://doi.org/10.1128/MCB.24.3.985-996.2004
Bestor TH (2000) The DNA methyltransferases of mammals. Hum Mol Genet 9(16):2395–2402. https://doi.org/10.1093/hmg/9.16.2395
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769–784. https://doi.org/10.1038/nrd2133
Borrello IM, Levitsky HI, Stock W et al (2009) Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114(9):1736–1745. https://doi.org/10.1182/blood-2009-02-205278
Borthakur G, Popplewell L, Boyiadzis M et al (2016) Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer 122(12):1871–1879. https://doi.org/10.1002/cncr.29986
Borun TW, Scharff MD, Robbins E (1969) Rapidly labeled, polyribosome-associated RNA having the properties of histone messenger. Proc Natl Acad Sci USA 58(5):1977–1983
Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra38. https://doi.org/10.1126/scitranslmed.3005930
Bross PF, Beitz J, Chen G et al (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490–1496
Byrd JC, Mrozek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336. https://doi.org/10.1182/blood-2002-03-0772
Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074. https://doi.org/10.1056/NEJMoa1301689
Carbone R, Botrugno OA, Ronzoni S et al (2006) Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 26(4):1288–1296. https://doi.org/10.1128/MCB.26.4.1288-1296.2006
Carow CE, Levenstein M, Kaufmann SH et al (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87(3):1089–1096
Challen GA, Sun D, Jeong M et al (2011) DNMT3A is essential for hematopoietic stem cell differentiation. Nat Genet 44(1):23–31. https://doi.org/10.1038/ng.1009
Chan SM, Thomas D, Corces-Zimmerman MR et al (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21(2):178–184. https://doi.org/10.1038/nm.3788
Chaturvedi A, Araujo Cruz MM, Jyotsana N et al (2013) Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122(16):2877–2887. https://doi.org/10.1182/blood-2013-03-491571
Chaturvedi A, Araujo Cruz M, Goparaju R et al (2014) A novel inhibitor of mutant IDH1 induces differentiation in vivo and prolongs survival in a mouse model of leukemia. 56th ASH Annual meeting and exhibition. 6–9 December 2014, San Francisco CA, USA. Blood 124(21):3598
Chen GQ, Shi XG, Tang W et al (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I, As2O3 exerts dosedependent dual effects on APL cells. Blood 89(9):3345–3353
Chowdhury R, Yeoh KK, Tian YM et al (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12(5):463–469. https://doi.org/10.1038/embor.2011.43
Cimino G, Lo-Coco F, Fenu S et al (2006) Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and highrisk acute myeloid leukemia. Cancer Res 66(17):8903–8911. https://doi.org/10.1158/0008-5472.CAN-05-2726
Cohen SS (1966) Introduction to the biochemistry of d-arabinosyl nucleosides. Prog Nucleic Acid Res Mol Biol 5:1–88
Colombo E, Marine JC, Danovi D et al (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4(7):529–533. https://doi.org/10.1038/ncb814
Colovic N, Tosic N, Aveic S et al (2007) Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. Ann Hematol 86(10):741–747. https://doi.org/10.1007/s00277-007-0325-3
Creasey WA, Deconti RC, Kaplan SR (1968) Biochemical studies with 1-β-d-arabinofuranosylcytosine in human leukemic leukocytes and normal bone marrow cells. Cancer Res 28(6):1074–1081
Curti A, Ruggeri L, D’Addio A et al (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118(12):3273–3279. https://doi.org/10.1182/blood-2011-01-329508
Daigle SR, Olhava EJ, Therkelsen CA et al (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122(6):1017–1025. https://doi.org/10.1182/blood-2013-04-497644
Damm F, Markus B, Thol F et al (2014) TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. Genes Chromosomes Cancer 53(10):824–832. https://doi.org/10.1002/gcc.22191
Dang L, White DW, Gross S et al (2009) Cancer associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739–744. https://doi.org/10.1038/nature08617
Davis MI, Gross S, Shen M et al (2014) Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 289(20):13717–13725. https://doi.org/10.1074/jbc.M113.511030
Dawson MA, Prinjha RK, Dittmann A et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529–533. https://doi.org/10.1038/nature10509
Dicker F, Haferlach C, Kern W et al (2007) Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 110(4):1308–1316. https://doi.org/10.1182/blood-2007-02-072595
Dohner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196
Dombret H, Preudhomme C, Berthon C et al (2014) A phase 1 study of the BET-Bromodomain inhibitor OTX015 in patients with advanced acute leukemia. 56th ASH Annual Meeting and http://www.bloodjournal.org/content/124/21/117 Exposition. 6–9 December 2014, San Francisco CA, USA. Blood 124(21):117
Dutour A, Marin V, Pizzitola I et al (2012) In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol 2012:683065. https://doi.org/10.1155/2012/683065
Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457–463. https://doi.org/10.1038/nature02625
El Hajj H, Dassouki Z, Berthier C et al (2015) Retinoic acid and arsenic trioxide trigger degradation of mutated NPM-1 resulting in apoptosis of AML cells. Blood 125(22):3447–3454. https://doi.org/10.1182/blood-2014-11-612416
Emadi A, Karp JE (2012) The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics 13(11):1257–1269. https://doi.org/10.2217/pgs.12.102
Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90(2):720–724
Estey E, Garcia-Manero G, Ferrajoli A et al (2006) Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107(9):3469–3473. https://doi.org/10.1182/blood-2005-10-4006
Falini B, Martelli MP (2011) NPM1-mutated AML: targeting by disassembling. Blood 118(11):2936–2938. https://doi.org/10.1182/blood-2011-07-366146
Falini B, Albiero E, Bolli N et al (2007) Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia 21(9):2052–2054. https://doi.org/10.1038/sj.leu.2404839
Falini B, Sportoletti P, Martelli MP (2009) Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 21(6):573–581. https://doi.org/10.1097/CCO.0b013e3283313dfa
Falini B, Martelli MP, Bolli N et al (2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 117(4):1109–1120. https://doi.org/10.1182/blood-2010-08-299990
Figueroa ME, Reimers M, Thompson RF et al (2008) An integrative genomic and epigenomic approach for the study of transcriptional regulation. PloS ONE 3(3):e1882. https://doi.org/10.1371/journal.pone.0001882
Figueroa ME, Abdel-Wahab O, Lu C (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553–567. https://doi.org/10.1016/j.ccr.2010.11.015
Fredly H, Gjertsen BT, Bruserud O (2013) Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics 5(1):12. https://doi.org/10.1186/1868-7083-5-12
Gaidzik VI, Paschka P, Späth D et al (2012) TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 30(12):1350–1357. https://doi.org/10.1200/JCO.2011.39.2886
Galmarini CM, Thomas X, Calvo F et al (2002) Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26:621–629. https://doi.org/10.1016/S0145-2126(01)00184-9
Galmarini CM, Cros E, Thomas X et al (2005) The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica 90(12):1699–1701
Gill S, June CH (2015) Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263(1):68–89. https://doi.org/10.1111/imr.12243
Gleason MK, Ross JA, Warlick ED et al (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123(19):3016–3026. https://doi.org/10.1182/blood-2013-10-533398
Grignani F, De Matteis S, Nervi C et al (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391(6669):815–818. https://doi.org/10.1038/35901
Groschel S, Sanders MA, Hoogenboezem R et al (2015) Mutational spectrum of myeloid malignancies with inv(3)/t(3,3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood 125(1):133–139. https://doi.org/10.1182/blood-2014-07-591461
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hardwick N, Chan L, Ingram W et al (2010) Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL 2 and CD80. Cancer Immunol Immunother 59(3):379–388. https://doi.org/10.1007/s00262-009-0756-x
Hartford CM, Duan S, Delaney SM et al (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10):2145–2153. https://doi.org/10.1182/blood-2008-05-154302
Iacobucci I, Lonetti A, Candoni A et al (2013) Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J 13(4):335–341. https://doi.org/10.1038/tpj.2012.13
Issa JP, Garcia-Manero G, Giles FJ et al (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635–1640. https://doi.org/10.1182/blood-2003-03-0687
Itzykson R, Kosmider O, Cluzeau T et al (2011) Impact of TET2 mutations on response rate to azacitidine inmyelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25(7):1147–1152. https://doi.org/10.1038/leu.2011.71
Jena B, Dotti G, Cooper LJ (2010) Redirecting T cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7):1035–1044. https://doi.org/10.1182/blood-2010-01-043737
Jordan CT, Upchurch D, Szilvassy SJ et al (2000) The interleukin-3 receptor alpha chain is a unique marker for humanacute myelogenous leukemia stem cells. Leukemia 14:1777–1784
Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670–2677. https://doi.org/10.1200/JCO.2011.38.9429
Keilholz U, Letsch A, Busse A et al (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113(26):6541–6548. https://doi.org/10.1182/blood-2009-02-202598
Kenderian SS, Ruella M, Shestova O et al (2015) CD33 specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29(8):1637–1647. https://doi.org/10.1038/leu.2015.52
Kim JH, Lee C, Cheong HS et al (2016) SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia. Cancer Chemother Pharmacol 78(3):533–540. https://doi.org/10.1007/s00280-016-3103-x
Kim S, Poursine-Laurent J, Truscott SM et al (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436(7051):709–713. https://doi.org/10.1038/nature03847
Knutson SK, Wigle TJ, Warholic NM et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8(11):890–896. https://doi.org/10.1038/nchembio.1084
Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7(11):823–833. https://doi.org/10.1038/nrc2253
Krstovski N, Tosic N, Janic D et al (2010) Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature. Med Oncol 27:640–645. https://doi.org/10.1007/s12032-009-9261-5
Krupka C, Kufer P, Kischel R et al (2014) CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 123(3):356–365. https://doi.org/10.1182/blood-2013-08-523548
Kuball J, de Boer K, Wagner E et al (2011) Pitfalls of vaccinations with WT1, Proteinase3 and MUC1 derived peptides in combination with MontanidISA51 and CpG7909. Cancer Immunol Immunother 60(2):161–171. https://doi.org/10.1007/s00262-010-0929-7
Kugler M, Stein C, Kellner C et al (2010) A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 150(5):574–586. https://doi.org/10.1111/j.1365-2141.2010.08300.x
Kung Sutherland MS, Walter RB, Jeffrey SC et al (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122(8):1455–1463. https://doi.org/10.1182/blood-2013-03-491506
Kuzmanovic M, Tosic N, Colovic N et al (2012) Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. Acta Haematol 128:203–212. https://doi.org/10.1159/000339506
L’Ecuyer T, Allebban Z, Thomas R, Vander Heide R (2004) Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ Physiol 286(6):H2057–H2064. https://doi.org/10.1152/ajpheart.00778.2003
Lamba JK (2009) Genetic factors influencing cytarabine therapy. Pharmacogenomics 10(10):1657–1674. https://doi.org/10.2217/pgs.09.118
Lamba JK, Crews K, Pounds S et al (2007) Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 323:935–945. https://doi.org/10.1124/jpet.107.128595
Lee JJ, Kook H, Park MS et al (2004) Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher 19(2):66–70. https://doi.org/10.1002/jca.10080
Levis MJ, Perl AE, Altman JK et al (2015) Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). 51th ASCO Annual Meeting; May 29 - June 2,Chicago, IL, USA. J Clin Oncol 33(15)suppl:7003. https://doi.org/10.1200/jco.2015.33.15_suppl.7003
Ley TJ, Mardis ER, Ding L et al (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218):66–72. https://doi.org/10.1038/nature07485
Ley TJ, Ding L, Walter MJ et al (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363(25):2424–2433. https://doi.org/10.1056/NEJMoa1005143
Li L, Fridley B, Kalari K et al (2008) Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 68(17):7050–7058. https://doi.org/10.1158/0008-5472.CAN-08-0405
Lindsley RC, Ebert BL (2013) The biology and clinical impact of genetic lesions in myeloid malignancies. Blood 122(23):3741–3748. https://doi.org/10.1182/blood-2013-06-460295
Lutterbach B, Hou Y, Durst KL, Heibert SW (1999) The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci USA 96(22):12822–12827
Macdonald DA, Assouline SE, Brandwein J et al (2013) A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk Lymphoma 54(4):760–766. https://doi.org/10.3109/10428194.2012.737917
Marcucci G, Maharry K, Wu YZ et al (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28(14):2348–2355. https://doi.org/10.1200/JCO.2009.27.3730
Marcucci G, Metzeler KH, Schwind S et al (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30(7):742–750. https://doi.org/10.1200/JCO.2011.39.2092
Mardiros A, Forman SJ, Budde LE (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22(6):484–488. https://doi.org/10.1097/MOH.0000000000000190
Mardis ER, Ding L, Dooling DJ et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058–1066. https://doi.org/10.1056/NEJMoa0903840
Maring JG, Groen HJ, Wachters FM et al (2005) Genetic factors influencing pyrimidine antagonist chemotherapy. Pharmacogenomics J 5(4):226–243. https://doi.org/10.1038/sj.tpj.6500320
Marjanovic I, Kostic J, Stanic B et al (2016) Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease. Tumour Biol 37(10):13391–13401. https://doi.org/10.1007/s13277-016-5142-7
Martelli MP, Gionfriddo I, Mezzasoma F et al (2015) Arsenic trioxide and all-trans-retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood 125(22):3455–3465. https://doi.org/10.1182/blood-2014-11-611459
Megías JE, Montesinos P, Herrero MJ et al (2015) Impact of transporter genes polymorphisms in standard induction of acute myeloid leukemia. Blood 126(23):4842. http://www.bloodjournal.org/content/126/23/4842
Mesa RA, Kaufmann SH (2007) Altered apoptosis in AML: potential implications for pathogenesis and therapeutic response. In: Karp JE (ed) Acute myeloid leukemia. Springer, Berlin, pp 133–161. https://doi.org/10.1007/978-1-59745-322-6_6
Metzeler KH, Walker A, Geyer S et al (2012) DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 26(5):1106–1107. https://doi.org/10.1038/leu.2011.342
Meyers S, Lenny N, Hiebert SW (1995) The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 15(4):1974–1982
Mitra AK, Crews KR, Pounds S et al (2011) Genetic variants in cytosolic 5′-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther 339(1):9–23. https://doi.org/10.1124/jpet.111.182873
Montero TD, Racordon D, Bravo L et al (2012) PPARα and PPARγ regulate the nucleoside transporter hENT1. Biochem Biophys Res Commun 419(2):405–411. https://doi.org/10.1016/j.bbrc.2012.02.035
Moore AS, Faisal A, Gonzalez de Castro D et al (2012) Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 26(7):1462–1470. https://doi.org/10.1038/leu.2012.52
Nomdedeu J, Bussaglia E, Villamor N et al (2011) Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group. Leuk Res 35(2):163–168. https://doi.org/10.1016/j.leukres.2010.05.015
O’Hear C, Heiber JF, Schubert I et al (2015) Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 100(3):336–344. https://doi.org/10.3324/haematol.2014.112748
Perry AM, Attar EC (2014) New insights in AML biology from genomic analysis. Semin Hematol 51(4):282–297. https://doi.org/10.1053/j.seminhematol.2014.08.005
Petersdorf SH, Kopecky KJ, Slovak M et al (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121(24):4854–4860. https://doi.org/10.1182/blood-2013-01-466706
Pizzitola I, Anjos-Afonso F, Rouault-Pierre K et al (2014) Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28(8):1596–1605. https://doi.org/10.1038/leu.2014.62
Ploen GG, Nederby L, Guldberg P et al (2014) Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol 167(4):478–486. https://doi.org/10.1111/bjh.13062
Pollard JA, Loken M, Gerbing RB et al (2016) CD33 Expression andiIts association with gemtuzumab ozogamicin response: Results from the randomized Phase III Children’s Oncology Group Trial AAML0531. J Clin Oncol 34(7):747–755. https://doi.org/10.1200/JCO.2015.62.6846
Puda A, Milosevic JD, Berg T et al (2012) Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol 87(3):245–250. https://doi.org/10.1002/ajh.22257
Randhawa JK, Kantarjian HM, Borthakur G et al (2014) Results of a phase II study of crenolanib in relapsed/refractory acutemyeloid leukemia patients (pts) with activating FLT3 mutations. 56th ASH Annual Meeting and Exposition. 6–9 December 2014, San Francisco CA, USA. Blood 124(21):389. https://ash.confex.com/ash/2014/webprogram/Paper74499.html
Ravandi F, Alattar ML, Grunwald MR et al (2013) Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655–4662. https://doi.org/10.1182/blood-2013-01-480228
Rotiroti MC, Arcangeli S, Casucci M et al (2017) Acute myeloid leukemia targeting by chimeric antigen receptor T cells: bridging the gap from preclinical modeling to human studies. Hum Gene Ther 28(3):231–241. https://doi.org/10.1089/hum.2016.092
Ruben JM, van den Ancker W, Bontkes HJ et al (2014) Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines. Cancer Immunol Immunother 63(4):335–345. https://doi.org/10.1007/s00262-013-1515-6
Rubnitz JE, Inaba H, Ribeiro RC et al (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28(6):955–959. https://doi.org/10.1200/JCO.2009.24.4590
Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100. https://doi.org/10.1126/science.1068440
Russler-Germain DA, Spencer DH, Young MA et al (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25(4):442–454. https://doi.org/10.1016/j.ccr.2014.02.010
Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388–398. https://doi.org/10.1158/2159-8290.CD-12-0548
Scaglioni PP, Pandolfi PP (2007) The theory of APL revisited. Curr Top Microbiol Immunol 313:85–100
Schnittger S, Schoch C, Dugas M et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100(1):59–66. https://doi.org/10.1182/blood.V100.1.59
Schnittger S, Haferlach C, Ulke M et al (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 116(25):5486–5196. https://doi.org/10.1182/blood-2010-02-267955
Serrano-López J, Sanchez-Garcia J, Serrano J et al (2011) Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia. Transfusion 51(7):1546–1555. https://doi.org/10.1111/j.1537-2995.2010.03042.x
Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9(1):105–127. https://doi.org/10.2217/14622416.9.1.105
Shlush LI, Zandi S, Mitchell A et al (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506(7488):328–333. https://doi.org/10.1038/nature13038
Skalova K, Mollova K, Michalek J (2010) Human myeloid dendritic cells for cancer therapy: does maturation matter? Vaccine 28(32):5153–5160. https://doi.org/10.1016/j.vaccine.2010.05.042
Smith CC, Lin K, Stecula A et al (2015) FLT3-D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 29(12):2390–2392. https://doi.org/10.1038/leu.2015.165
Speck NA, Gililand DG (2002) Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2(7):502–513. https://doi.org/10.1038/nrc840
Stein AS, Walter RB, Erba HP et al (2015) A phase I trial of SGN-CD33A as immunonotherapy in patients with CD33-positive acute myeloid leukemia (AML). 57th ASH Annual meeting and exhibition. 5-8 December 2015, Orlando FL, USA. Blood 126(23):324. https://ash.confex.com/ash/2015/webprogramscheduler/Paper83162.html
Stein EM (2015) IDH2 inhibition in AML: finally progress? Best Pract Res Clin Haematol 28(2-3):112–115. https://doi.org/10.1016/j.beha.2015.10.016
Stein EM, Tallman MS (2015) Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L. Curr Opin Hematol 22(2):92–96. https://doi.org/10.1097/MOH.0000000000000123
Stone RM, Mandrekar S, Sanford BL et al (2015) The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY). 57th ASH Annual Meeting & Exposition; 5–8 December 2015, Orlando, FL, USA. Blood 126(23):6. https://ash.confex.com/ash/2015/webprogram/Paper80269.html
Strahl B, Allis C (2000) The language of covalent histone modifications. Nature 403(6765):41–45. https://doi.org/10.1038/47412
Takagaki K, Katsuma S, Horio T et al (2003) cDNA microarray analysis of altered gene expression in Ara-C-treated leukemia cells. Biochem Biophys Res Commun 309(2):351–358. https://doi.org/10.1016/j.bbrc.2003.08.009
Tallman MS, Andersen JW, Schiffer CA et al (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup Protocol. Blood 100(13):4298–4302. https://doi.org/10.1182/blood-2002-02-0632
Thol F, Damm F, Wagner K et al (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116(4):614–616. https://doi.org/10.1182/blood-2010-03-272146
Traulsen A, Pacheco JM, Luzzatto L, Dingli D (2010) Somatic mutations and the hierarchy of hematopoiesis. Bioessays 32(11):1003–1008. https://doi.org/10.1002/bies.201000025
Uttenthal B, Martinez-Davila I, Ivey A et al (2014) Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 164(3):366–375. https://doi.org/10.1111/bjh.12637
Uttenthal BJ, Chua I, Morris EC, Stauss HJ (2012) Challenges in T cell receptor gene therapy. J Gene Med 14(6):386–399. https://doi.org/10.1002/jgm.2637
Valent P, Zuber J (2014) BRD4: a BET (ter) target for the treatment of AML? Cell Cycle 13(5):689–690. https://doi.org/10.4161/cc.27859
Van Driessche A, Van de Velde AL, Nijs G et al (2009) Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a Phase I dose-escalation clinical trial. Cytotherapy 11(5):653–668. https://doi.org/10.1080/14653240902960411
Van Tendeloo VF, Van de Velde A, Van Driessche A et al (2010) Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 107(31):13824–13829. https://doi.org/10.1073/pnas.1008051107
Villa R, Pasini D, Gutierrez A et al (2007) Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11(6):513–525. https://doi.org/10.1016/j.ccr.2007.04.009
Virijevic M, Karan-Djurasevic T, Marjanovic I et al (2016) Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. Radiol Oncol 50(4):385–393. https://doi.org/10.1515/raon-2016-0044
Voso MT, Hohaus S, Guidi F et al (2008) Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 22(9):1685–1691. https://doi.org/10.1038/leu.2008.169
Wagner K, Damm F, Göhring G et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an Adverse Prognostic Factor. J Clin Oncol 28(14):2356–2364. https://doi.org/10.1200/JCO.2009.27.6899
Wan H, Zhu J, Chen F et al (2014) SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res 33(1):90. https://doi.org/10.1186/s13046-014-0090-9
Wang F, Travins J, De La Barre B et al (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340(6132):622–626. https://doi.org/10.1126/science.1234769
Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111(5):2505–2515. https://doi.org/10.1182/blood-2007-07-102798
Ward PS, Patel J, Wise DR et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-ketoglutarate to 2- hydrozyglutarate. Cancer Cell 17(3):225–234. https://doi.org/10.1016/j.ccr.2010.01.020
Warner JK, Wang JCY, Hope KJ et al (2004) Concepts of human leukemic developement. Oncogene 23(43):7164–7177. https://doi.org/10.1038/sj.onc.1207933
Wei A, Tan P, Perruzza S et al (2015) Maintenance lenalidomide in combination with 5-azacytidine as post remission therapy for acute myeloid leukemia. Br J Haematol 169(2):199–210. https://doi.org/10.1111/bjh.13281
Welch JS, Westervelt P, Ding L et al (2011) Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305(15):1577–1584. https://doi.org/10.1001/jama.2011.497
Wolf CR, Smith G, Smith RL (2000) Science, medicine, and the future: Pharmacogenetics. BMJ 320(7240):987–990
Xie M, Lu C, Wang J et al (2014) Age related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20(12):1472–1478. https://doi.org/10.1038/nm.3733
Xu W, Yang H, Liu Y et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate dependent dioxygenases. Cancer Cell 19(1):17–30. https://doi.org/10.1016/j.ccr.2010.12.014
Yamamoto Y, Kiyoi H, Nakano Y et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8):2434–2439. https://doi.org/10.1182/blood.V97.8.2434
Yin B, Tsai ML, Hasz DE et al (2007) A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia 21(5):1093–1097. https://doi.org/10.1038/sj.leu.2404595
Zarrinkar PP, Gunawardane RN, Cramer MD et al (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114(14):2984–2992. https://doi.org/10.1182/blood-2009-05-222034
Zhang W, Konopleva M, Shi YX et al (2008a) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100(3):184–198. https://doi.org/10.1093/jnci/djm328
Zhang W, Konopleva M, Shi YX et al (2008b) Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22(4):808–818. https://doi.org/10.1038/sj.leu.2405098
Ziv O, Zeisel A, Mirlas-Neisberg N et al (2014) Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin. Nat Commun 5:5437. https://doi.org/10.1038/ncomms6437
Acknowledgments
This work funded by the Ministry of Education, Science and Technological Development, Republic of Serbia (grant no. III 41004).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pavlović, S., Tosic, N. (2019). Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia. In: Bodiroga-Vukobrat, N., Rukavina, D., Pavelić, K., Sander, G.G. (eds) Personalized Medicine in Healthcare Systems. Europeanization and Globalization, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-030-16465-2_28
Download citation
DOI: https://doi.org/10.1007/978-3-030-16465-2_28
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16464-5
Online ISBN: 978-3-030-16465-2
eBook Packages: Law and CriminologyLaw and Criminology (R0)